EP300 and neoplasm: The redundant targets of CREBBP and EP300 may be essential for tumor cell survival because DLBCL cell lines with truncating mutations of CREBBP are sensitive to knock-out or pharmacologic inhibition of EP300 (Meyer et al., 2019).